Topical ophthalmic cyclosporine: pharmacology and clinical uses.
about
Novel formulations for antimicrobial peptidesCorneal nerves in health and diseaseTreatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.Reducing peak corneal haze after photorefractive keratectomy in rabbits: prednisolone acetate 1.00% versus cyclosporine A 0.05%Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery.Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline.Cyclosporine immunomodulation retards regeneration of surgically transected corneal nerves.Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye diseaseUltra-high resolution optical coherence tomography for monitoring tear meniscus volume in dry eye after topical cyclosporine treatment.Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome.Longitudinal evidence on punctal plug use in an elderly populationNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.The effect of topical cyclosporine 0.05% on dry eye after cataract surgery.Conjunctival sarcoidosis presenting as limbal conjunctival hypertrophy: a case report.A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.Clinical review: topical ophthalmic use of cyclosporin A.New agents for treating dry eye syndrome.Graft versus host disease: clinical evaluation, diagnosis and management.Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca.Classification criteria and treatment modalities in primary Sjögren's syndrome.The role and treatment of inflammation in dry eye disease.Systemic cyclosporine and corneal transplantation.Understanding Neuropathic Corneal Pain--Gaps and Current Therapeutic Approaches.In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants.Anti-inflammatory effects of resolvin-D1 on human corneal epithelial cells: in vitro studySupercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsionEffects of Lycium barbarum (goji berry) on dry eye disease in rats.The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research.Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis.Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases.Keratitis in Dry Eye Disease and Topical Ciclosporin A.Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study.Corneal refractive surgery-related dry eye: risk factors and managementAn overview on dry eye treatment: approaches for cyclosporin a deliveryOnce-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease
P2860
Q26991771-D0A7FD29-D79E-4B59-8E1D-8D594FE6982CQ27002347-6EDE24DE-AF3D-4220-938A-039C3CE8EFF9Q33543585-5BDEBF08-6B74-4C35-B668-137158CD69CFQ33846813-AF4D09D0-1877-4C82-8ACF-E50ACA663ACDQ35565484-9BC9979F-B10D-40C0-9646-B4F0830869B9Q35691929-78CFC4EC-0C69-4C10-9510-C6D0881B9492Q35865430-392E4570-3090-45FA-A11F-6A201BB3E795Q35907009-A412F54A-AEDE-48B5-AEB1-71428785FEFFQ36085236-5EC06C15-8491-4851-A58D-97DF935EA34FQ36413214-4D88AA02-4F99-4FA4-8F42-54A78E64A4B6Q36469760-6B8C1A20-1614-4959-A322-10D493D8002CQ36766324-91EA83AD-ADFD-4E99-9525-1F9E78AD4436Q36872338-A3F5924B-0C6B-4444-A791-4B6ED2256921Q37618841-B2868337-E8D7-4AA4-B30F-227BD085279FQ37719148-FE0BFE80-9865-421E-AA44-4F298C04D994Q37782084-8FCCD82B-C9D5-4B00-9358-F693C798D260Q38058002-8321A361-C56D-45B2-BE7B-62863769CDD5Q38090503-1F04F03C-C203-4DC3-A78B-D38ED5C2C576Q38176265-991FA83B-2A61-42DB-A776-023A0DAD8CB9Q38197287-D306F8A8-7748-4579-8949-E0B319D17BE3Q38270449-E5C98A25-83D3-484E-B527-E1532893562AQ38606422-131EC3F7-92A8-4B6A-B67B-E2848884EFDFQ38766815-F36894C6-F6B4-4FFF-BA60-0DC2B59177BFQ39878699-0CE154C0-5244-41AC-B5B7-9EC2C5E09AC9Q41999352-93CC0FCE-DA18-40E2-B111-2F6443747DC6Q42792794-3CAA9CB1-6ACB-467C-A23D-E9124302EE2AQ47715552-B31D567F-45BE-4457-8532-915AD0964654Q47884949-DA175591-157E-4FF0-86C0-4B27AAD42A48Q48126820-231BC63A-0348-420D-9451-EC3E075E65F2Q52666978-CEC1A5FC-1862-43A4-9210-1B95A4D09CF6Q53534950-6218363B-8F59-4C49-B6E9-534ADF9DC240Q53558849-77EA3FBB-C387-4B64-96A2-B354AD63C830Q56775749-0EAA4387-3596-4169-A548-440DCDD1298EQ57378877-98EA2F9E-15C1-4733-B874-6506C8DFE75DQ57479273-F8208DFB-9CA1-4984-8640-8D8ACF78F907
P2860
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@en
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@nl
type
label
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@en
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@nl
prefLabel
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@en
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@nl
P1476
Topical ophthalmic cyclosporine: pharmacology and clinical uses.
@en
P2093
Eric Donnenfeld
Stephen C Pflugfelder
P304
P356
10.1016/J.SURVOPHTHAL.2009.02.002
P577
2009-05-01T00:00:00Z